ProShare Advisors
ABOS icon

ProShare Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

ProShare Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,812
Closed -$20.3K – 2083
2024
Q4 		$20.3K Buy
+11,812
New +$28.4K ﹤0.01% 2256

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

ProShare Advisors's ABOS Position: Q1 2025 in Review

ProShare Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2025, closing a stake of 11,812 shares — an estimated $20.3K sold.

ProShare Advisors first reported a position in ABOS in Q4 2024 and held it in 1 quarter. The position peaked at $20.3K in Q4 2024. 81 funds tracked by Wall St. Rank hold ABOS as of Q1 2025.

  • ProShare Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • ProShare Advisors sold 11,812 Acumen Pharmaceuticals shares in Q1 2025, an estimated $20.3K.
  • ProShare Advisors first reported a position in Acumen Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • ProShare Advisors's Acumen Pharmaceuticals position peaked at $20.3K in Q4 2024.
  • 81 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.